PHASE-II TRIAL OF PIPERAZINEDIONE IN MALIGNANT-MELANOMA - REPORT BY THE SOUTHEASTERN-CANCER-STUDY-GROUP

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (8) , 1367-1369
Abstract
Evaluable patients (41) with malignant melanoma resistant to other chemotherapeutic agents received 9 mg/m2 of piperazinedione every 3 wk. Two patients had partial responses and 1 additional patient had stable disease. One of the partial responses occurred in a patient with subcutaneous metastases and the other occurred in a patient with pulmonary and osseous metastases. Both antitumor responses occurred in the 17 patients with a performance status of .gtoreq. 80%. The dose-limiting toxicity was myelosuppression; thrombocytopenia was more frequently observed than granulocytopenia.

This publication has 0 references indexed in Scilit: